| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 14 | 2022 | 794 | 2.160 |
Why?
|
| Naphthoquinones | 5 | 2020 | 35 | 1.840 |
Why?
|
| Antineoplastic Agents | 15 | 2019 | 756 | 1.780 |
Why?
|
| Benzamides | 6 | 2018 | 76 | 1.430 |
Why?
|
| Apoptosis | 9 | 2020 | 1317 | 1.390 |
Why?
|
| Enzyme Inhibitors | 8 | 2019 | 396 | 1.220 |
Why?
|
| Pyridones | 6 | 2018 | 40 | 1.210 |
Why?
|
| Receptors, Calcitriol | 4 | 2020 | 59 | 1.080 |
Why?
|
| Parkinson Disease | 3 | 2022 | 167 | 0.990 |
Why?
|
| Vitamin D | 3 | 2022 | 176 | 0.900 |
Why?
|
| MicroRNAs | 3 | 2023 | 386 | 0.890 |
Why?
|
| Cell Line, Tumor | 25 | 2022 | 2128 | 0.820 |
Why?
|
| Tamoxifen | 1 | 2020 | 61 | 0.760 |
Why?
|
| Nicotine | 5 | 2020 | 238 | 0.750 |
Why?
|
| Neuroprotective Agents | 4 | 2022 | 231 | 0.740 |
Why?
|
| Antiparkinson Agents | 1 | 2019 | 11 | 0.720 |
Why?
|
| Humans | 54 | 2023 | 34853 | 0.710 |
Why?
|
| Nerve Growth Factors | 1 | 2019 | 33 | 0.700 |
Why?
|
| Isoquinolines | 3 | 2015 | 40 | 0.700 |
Why?
|
| Breast Neoplasms | 4 | 2021 | 1426 | 0.700 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 53 | 0.700 |
Why?
|
| Emetine | 2 | 2015 | 13 | 0.680 |
Why?
|
| Cell Proliferation | 13 | 2018 | 1149 | 0.590 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 406 | 0.590 |
Why?
|
| Histones | 7 | 2017 | 177 | 0.590 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 109 | 0.570 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2016 | 8 | 0.570 |
Why?
|
| RNA | 1 | 2018 | 234 | 0.560 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 430 | 0.560 |
Why?
|
| Enzyme Assays | 1 | 2016 | 11 | 0.560 |
Why?
|
| Methylation | 11 | 2019 | 102 | 0.550 |
Why?
|
| Lymphoma, B-Cell | 2 | 2018 | 22 | 0.550 |
Why?
|
| Ditiocarb | 1 | 2015 | 4 | 0.550 |
Why?
|
| Cell Survival | 7 | 2020 | 818 | 0.550 |
Why?
|
| Suntan | 1 | 2014 | 5 | 0.520 |
Why?
|
| Inhibitory Concentration 50 | 6 | 2020 | 81 | 0.520 |
Why?
|
| Histone-Lysine N-Methyltransferase | 6 | 2018 | 25 | 0.520 |
Why?
|
| Depression | 2 | 2022 | 664 | 0.490 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2020 | 638 | 0.480 |
Why?
|
| Methyltransferases | 5 | 2018 | 56 | 0.480 |
Why?
|
| Lysine | 4 | 2017 | 104 | 0.460 |
Why?
|
| Cataract Extraction | 1 | 2013 | 16 | 0.450 |
Why?
|
| Cataract | 1 | 2013 | 26 | 0.450 |
Why?
|
| Point Mutation | 3 | 2014 | 88 | 0.440 |
Why?
|
| Pyrimidines | 3 | 2017 | 112 | 0.420 |
Why?
|
| Orbital Neoplasms | 1 | 2011 | 1 | 0.410 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2011 | 2 | 0.400 |
Why?
|
| Facial Neoplasms | 1 | 2011 | 6 | 0.400 |
Why?
|
| Lymphoma, T-Cell | 1 | 2011 | 25 | 0.400 |
Why?
|
| Neuroblastoma | 4 | 2022 | 128 | 0.390 |
Why?
|
| Benzimidazoles | 3 | 2017 | 36 | 0.390 |
Why?
|
| Androgens | 2 | 2011 | 87 | 0.390 |
Why?
|
| Biphenyl Compounds | 7 | 2018 | 52 | 0.380 |
Why?
|
| Neoplasms | 2 | 2018 | 1033 | 0.380 |
Why?
|
| Killer Cells, Natural | 1 | 2011 | 86 | 0.380 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 16 | 0.370 |
Why?
|
| Male | 22 | 2022 | 18870 | 0.370 |
Why?
|
| Cell Cycle | 6 | 2014 | 309 | 0.350 |
Why?
|
| Neurotoxins | 2 | 2007 | 52 | 0.350 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 446 | 0.320 |
Why?
|
| Protein-Arginine N-Methyltransferases | 2 | 2019 | 3 | 0.310 |
Why?
|
| Ultraviolet Rays | 2 | 2020 | 116 | 0.310 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 522 | 0.300 |
Why?
|
| Drug Synergism | 4 | 2020 | 171 | 0.300 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2017 | 7 | 0.300 |
Why?
|
| Ethanol | 3 | 2021 | 188 | 0.290 |
Why?
|
| Kinetics | 4 | 2016 | 650 | 0.290 |
Why?
|
| Morpholines | 5 | 2018 | 65 | 0.280 |
Why?
|
| Transcription Factors | 1 | 2010 | 653 | 0.270 |
Why?
|
| Female | 17 | 2023 | 19873 | 0.270 |
Why?
|
| Leukemia | 2 | 2017 | 54 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2018 | 984 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 781 | 0.260 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 528 | 0.250 |
Why?
|
| RNA, Messenger | 4 | 2021 | 1152 | 0.250 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2014 | 37 | 0.250 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2003 | 19 | 0.230 |
Why?
|
| Adult | 9 | 2022 | 11034 | 0.220 |
Why?
|
| Animals | 15 | 2018 | 14307 | 0.220 |
Why?
|
| Middle Aged | 12 | 2022 | 9642 | 0.210 |
Why?
|
| Blotting, Western | 3 | 2010 | 834 | 0.210 |
Why?
|
| Prognosis | 3 | 2021 | 707 | 0.210 |
Why?
|
| Cell Death | 6 | 2020 | 260 | 0.210 |
Why?
|
| Butyric Acid | 1 | 2021 | 17 | 0.210 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 119 | 0.200 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 485 | 0.200 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2021 | 32 | 0.200 |
Why?
|
| Aged | 9 | 2021 | 6448 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 178 | 0.200 |
Why?
|
| Binding Sites | 3 | 2016 | 597 | 0.200 |
Why?
|
| Sunbathing | 1 | 2020 | 6 | 0.200 |
Why?
|
| Receptor, erbB-2 | 1 | 2021 | 122 | 0.190 |
Why?
|
| Butyrates | 1 | 2020 | 31 | 0.190 |
Why?
|
| DNA Methylation | 3 | 2018 | 301 | 0.190 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 600 | 0.190 |
Why?
|
| Risk | 3 | 2015 | 256 | 0.180 |
Why?
|
| Gene Rearrangement | 2 | 2017 | 15 | 0.180 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2019 | 2 | 0.180 |
Why?
|
| Receptors, Nicotinic | 1 | 2020 | 91 | 0.180 |
Why?
|
| Dopamine | 3 | 2022 | 232 | 0.170 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 416 | 0.160 |
Why?
|
| Spiro Compounds | 1 | 2017 | 10 | 0.160 |
Why?
|
| Isoxazoles | 1 | 2017 | 11 | 0.160 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2017 | 11 | 0.160 |
Why?
|
| Guanylate Cyclase | 1 | 2017 | 17 | 0.160 |
Why?
|
| Microfluidics | 1 | 2018 | 39 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 32 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 19 | 0.160 |
Why?
|
| Prostate-Specific Antigen | 2 | 2015 | 95 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2017 | 80 | 0.150 |
Why?
|
| Comorbidity | 1 | 2019 | 606 | 0.150 |
Why?
|
| Catalysis | 2 | 2010 | 162 | 0.150 |
Why?
|
| Neoplasm Transplantation | 5 | 2017 | 114 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 484 | 0.150 |
Why?
|
| Flow Cytometry | 2 | 2009 | 392 | 0.150 |
Why?
|
| Binding, Competitive | 1 | 2016 | 103 | 0.140 |
Why?
|
| Small Molecule Libraries | 2 | 2018 | 43 | 0.140 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2015 | 4 | 0.130 |
Why?
|
| Zanthoxylum | 1 | 2015 | 4 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 209 | 0.130 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 33 | 0.130 |
Why?
|
| Protein Binding | 4 | 2019 | 913 | 0.130 |
Why?
|
| Growth Inhibitors | 1 | 2014 | 23 | 0.130 |
Why?
|
| Sunlight | 1 | 2014 | 46 | 0.130 |
Why?
|
| Nucleus Accumbens | 2 | 2007 | 80 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2020 | 1056 | 0.130 |
Why?
|
| Metabolomics | 1 | 2014 | 76 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 29 | 0.120 |
Why?
|
| Age Factors | 1 | 2017 | 1007 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2017 | 242 | 0.120 |
Why?
|
| Smoking | 1 | 2020 | 903 | 0.120 |
Why?
|
| Rhabdoid Tumor | 1 | 2013 | 1 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2015 | 287 | 0.110 |
Why?
|
| Indazoles | 1 | 2012 | 9 | 0.110 |
Why?
|
| Eye Infections, Viral | 1 | 2012 | 4 | 0.110 |
Why?
|
| Lymphoma | 1 | 2012 | 37 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 41 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2015 | 250 | 0.110 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2011 | 1 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2011 | 38 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2011 | 15 | 0.100 |
Why?
|
| Benzoxazoles | 1 | 2011 | 9 | 0.100 |
Why?
|
| Oxazoles | 1 | 2011 | 19 | 0.100 |
Why?
|
| Structure-Activity Relationship | 4 | 2015 | 376 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 142 | 0.100 |
Why?
|
| Mice | 7 | 2017 | 5668 | 0.100 |
Why?
|
| Molecular Structure | 3 | 2019 | 467 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 105 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 206 | 0.090 |
Why?
|
| Central Nervous System Depressants | 2 | 2007 | 37 | 0.090 |
Why?
|
| Nicotinic Agonists | 2 | 2007 | 68 | 0.090 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 8 | 0.090 |
Why?
|
| Catalytic Domain | 2 | 2014 | 97 | 0.090 |
Why?
|
| Drug Interactions | 2 | 2007 | 137 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1003 | 0.090 |
Why?
|
| RNA Interference | 2 | 2021 | 225 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 480 | 0.080 |
Why?
|
| Oxadiazoles | 1 | 2008 | 14 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 2333 | 0.080 |
Why?
|
| Drug Design | 3 | 2015 | 154 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 531 | 0.080 |
Why?
|
| Mice, SCID | 3 | 2014 | 143 | 0.080 |
Why?
|
| Crystallography, X-Ray | 3 | 2015 | 237 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 445 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 605 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 117 | 0.080 |
Why?
|
| Annexin A5 | 1 | 2007 | 24 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 383 | 0.080 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 27 | 0.080 |
Why?
|
| Parkinsonian Disorders | 1 | 2007 | 35 | 0.080 |
Why?
|
| Models, Molecular | 3 | 2019 | 751 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2007 | 75 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 75 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 245 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 180 | 0.070 |
Why?
|
| Time Factors | 2 | 2018 | 1681 | 0.070 |
Why?
|
| Tetrazolium Salts | 1 | 2005 | 36 | 0.070 |
Why?
|
| Conotoxins | 1 | 2005 | 18 | 0.070 |
Why?
|
| Thiazoles | 1 | 2005 | 71 | 0.070 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2017 | 10 | 0.060 |
Why?
|
| Substrate Specificity | 2 | 2019 | 186 | 0.060 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2003 | 33 | 0.060 |
Why?
|
| Scattering, Radiation | 1 | 2003 | 45 | 0.060 |
Why?
|
| CHO Cells | 1 | 2003 | 107 | 0.060 |
Why?
|
| Glycosylation | 1 | 2003 | 92 | 0.060 |
Why?
|
| Endopeptidases | 1 | 2003 | 58 | 0.060 |
Why?
|
| Cricetinae | 1 | 2003 | 217 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2022 | 70 | 0.060 |
Why?
|
| Rats | 4 | 2014 | 3261 | 0.050 |
Why?
|
| Lipid Bilayers | 1 | 2003 | 66 | 0.050 |
Why?
|
| Drosophila | 1 | 2003 | 133 | 0.050 |
Why?
|
| Light | 1 | 2003 | 180 | 0.050 |
Why?
|
| Ventral Tegmental Area | 1 | 2002 | 36 | 0.050 |
Why?
|
| Genomics | 1 | 2023 | 201 | 0.050 |
Why?
|
| Ligands | 1 | 2003 | 317 | 0.050 |
Why?
|
| Risk Factors | 2 | 2020 | 3414 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2017 | 1534 | 0.050 |
Why?
|
| ROC Curve | 1 | 2021 | 138 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2003 | 360 | 0.050 |
Why?
|
| Receptors, Virus | 1 | 2020 | 20 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2020 | 1802 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 859 | 0.050 |
Why?
|
| Peptides | 1 | 2003 | 308 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2003 | 436 | 0.050 |
Why?
|
| Cell Line | 1 | 2003 | 1289 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2019 | 82 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 275 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2019 | 150 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2018 | 9 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 179 | 0.040 |
Why?
|
| Osteonectin | 1 | 2018 | 7 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2018 | 25 | 0.040 |
Why?
|
| Mutation | 2 | 2017 | 1023 | 0.040 |
Why?
|
| Cell Size | 1 | 2018 | 42 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 459 | 0.040 |
Why?
|
| France | 1 | 2018 | 17 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 9 | 0.040 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 32 | 0.040 |
Why?
|
| Cadherins | 1 | 2018 | 82 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 608 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 2207 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2018 | 118 | 0.040 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2018 | 68 | 0.040 |
Why?
|
| Lung | 1 | 2020 | 413 | 0.040 |
Why?
|
| Adenine | 1 | 2017 | 43 | 0.040 |
Why?
|
| Exercise | 1 | 2022 | 524 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 114 | 0.040 |
Why?
|
| Piperidines | 1 | 2017 | 76 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 184 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 181 | 0.040 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2015 | 5 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2003 | 881 | 0.030 |
Why?
|
| snRNP Core Proteins | 1 | 2015 | 11 | 0.030 |
Why?
|
| Mecamylamine | 2 | 2007 | 14 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 117 | 0.030 |
Why?
|
| Vincristine | 1 | 2014 | 13 | 0.030 |
Why?
|
| Nicotinic Antagonists | 2 | 2007 | 28 | 0.030 |
Why?
|
| Prednisolone | 1 | 2014 | 13 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 968 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 26 | 0.030 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2014 | 31 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 569 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2014 | 43 | 0.030 |
Why?
|
| Dipeptides | 1 | 2014 | 29 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 52 | 0.030 |
Why?
|
| NAD | 1 | 2014 | 39 | 0.030 |
Why?
|
| Phytotherapy | 1 | 2015 | 62 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 152 | 0.030 |
Why?
|
| Metabolome | 1 | 2014 | 47 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2007 | 202 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 139 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2014 | 80 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 80 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 65 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1349 | 0.030 |
Why?
|
| Amino Acids | 1 | 2014 | 139 | 0.030 |
Why?
|
| Glutathione | 1 | 2014 | 160 | 0.030 |
Why?
|
| Models, Biological | 1 | 2017 | 642 | 0.030 |
Why?
|
| Rats, Nude | 1 | 2013 | 6 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 247 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2014 | 160 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 407 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 641 | 0.030 |
Why?
|
| Plant Roots | 1 | 2015 | 153 | 0.030 |
Why?
|
| Nucleosides | 1 | 2012 | 27 | 0.030 |
Why?
|
| Pyridines | 1 | 2013 | 113 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2013 | 350 | 0.030 |
Why?
|
| District of Columbia | 1 | 2012 | 68 | 0.030 |
Why?
|
| Ophthalmology | 1 | 2012 | 28 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 185 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2012 | 98 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 13 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 198 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1490 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 219 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 251 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2011 | 562 | 0.020 |
Why?
|
| Microdialysis | 1 | 2007 | 18 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2007 | 33 | 0.020 |
Why?
|
| United States | 1 | 2017 | 3894 | 0.020 |
Why?
|
| Prevalence | 1 | 2012 | 1425 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2008 | 281 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2007 | 107 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 255 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2007 | 323 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 2561 | 0.020 |
Why?
|
| Young Adult | 1 | 2012 | 4012 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2002 | 89 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 5035 | 0.010 |
Why?
|